Literature DB >> 9311855

Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus.

R P Johnson1, R L Glickman, J Q Yang, A Kaur, J T Dion, M J Mulligan, R C Desrosiers.   

Abstract

Although live attenuated vaccine strains of simian immunodeficiency virus (SIV) have proven highly effective in protecting macaques against challenge with pathogenic SIV strains, little is known about the mechanisms of protective immunity induced by these vaccines. We examined cytotoxic T-lymphocyte (CTL) responses against SIV in animals infected with SIVmac239delta nef (deficient in nef) or SIVmac239delta 3 (deficient in nef, vpr, and upstream sequences in U3). To enhance detection of SIV-specific CTL activity, we stimulated peripheral blood mononuclear cells with autologous B-lymphoblastoid cell lines which had been infected with recombinant vaccinia viruses expressing SIV proteins and subsequently inactivated with psoralen and UV light. Animals chronically infected with SIV239delta nef or SIV239delta 3 mounted vigorous CTL responses against the SIV Gag and Env proteins. This CTL activity was major histocompatibility class restricted and mediated by CD8+ T lymphocytes. CTL responses persisted at relatively high levels for more than 6 years after infection. Limiting dilution precursor frequency assays demonstrated that the frequency of SIV-specific CTLs was as high as 234 CTL precursors per 100,000 cells. Animals acutely infected with SIV239delta nef developed CTL activity by day 14 after infection, coincident with decreases in viral load. Animals acutely infected with SIV239delta 3 developed CTL responses within 4 weeks of infection. Thus, vaccination of juvenile or adult animals with SIV239delta nef or SIV239delta 3 results in the induction of a vigorous CTL response which arises early in the course of infection and persists for years after a single inoculation of virus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9311855      PMCID: PMC192122          DOI: 10.1128/JVI.71.10.7711-7718.1997

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells.

Authors:  N Almond; K Kent; M Cranage; E Rud; B Clarke; E J Stott
Journal:  Lancet       Date:  1995-05-27       Impact factor: 79.321

2.  The Thai response to the HIV/AIDS epidemic.

Authors:  J Ungphakorn; W Sittitrai
Journal:  AIDS       Date:  1994       Impact factor: 4.177

3.  A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge.

Authors:  B L Lohman; M B McChesney; C J Miller; E McGowan; S M Joye; K K Van Rompay; E Reay; L Antipa; N C Pedersen; M L Marthas
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

4.  Occurrence of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T cell activity in apparently uninfected children born to HIV-1-infected mothers.

Authors:  A De Maria; C Cirillo; L Moretta
Journal:  J Infect Dis       Date:  1994-11       Impact factor: 5.226

5.  Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus.

Authors:  J E Clements; R C Montelaro; M C Zink; A M Amedee; S Miller; A M Trichel; B Jagerski; D Hauer; L N Martin; R P Bohm
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

6.  Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques.

Authors:  T W Baba; Y S Jeong; D Pennick; R Bronson; M F Greene; R M Ruprecht
Journal:  Science       Date:  1995-03-24       Impact factor: 47.728

7.  A novel method for detection and ex vivo expansion of HIV type 1-specific cytolytic T lymphocytes.

Authors:  M N Lubaki; M A Egan; R F Siliciano; K J Weinhold; R C Bollinger
Journal:  AIDS Res Hum Retroviruses       Date:  1994-11       Impact factor: 2.205

8.  A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge.

Authors:  Y Yasutomi; S Koenig; R M Woods; J Madsen; N M Wassef; C R Alving; H J Klein; T E Nolan; L J Boots; J A Kessler
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

9.  Progression to AIDS in the absence of a gene for vpr or vpx.

Authors:  J S Gibbs; A A Lackner; S M Lang; M A Simon; P K Sehgal; M D Daniel; R C Desrosiers
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

10.  ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids.

Authors:  L A Pinto; J Sullivan; J A Berzofsky; M Clerici; H A Kessler; A L Landay; G M Shearer
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

View more
  55 in total

1.  Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1.

Authors:  N W Blake; A Moghaddam; P Rao; A Kaur; R Glickman; Y G Cho; A Marchini; T Haigh; R P Johnson; A B Rickinson; F Wang
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus.

Authors:  S A Hammond; F Li; B M McKeon; S J Cook; C J Issel; R C Montelaro
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

3.  Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection.

Authors:  S I Staprans; P J Dailey; A Rosenthal; C Horton; R M Grant; N Lerche; M B Feinberg
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

4.  Pathogenic simian/human immunodeficiency virus SHIV(KU) inoculated into immunized macaques caused infection, but virus burdens progressively declined with time.

Authors:  P S Silverstein; G A Mackay; S Mukherjee; Z Li; M Piatak; J D Lifson; O Narayan; A Kumar
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus.

Authors:  C G Murphy; W T Lucas; R E Means; S Czajak; C L Hale; J D Lifson; A Kaur; R P Johnson; D M Knipe; R C Desrosiers
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  Protection of macaques against AIDS with a live attenuated SHIV vaccine is of finite duration.

Authors:  Anil Kumar; Zhenqian Liu; Darlene Sheffer; Marilyn Smith; Dinesh K Singh; Shilpa Buch; Opendra Narayan
Journal:  Virology       Date:  2007-11-07       Impact factor: 3.616

7.  DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory.

Authors:  Mariana Manrique; Ewa Micewicz; Pamela A Kozlowski; Shainn-Wei Wang; Deepti Aurora; Robert L Wilson; Musie Ghebremichael; Gail Mazzara; David Montefiori; Angela Carville; Keith G Mansfield; Anna Aldovini
Journal:  AIDS Res Hum Retroviruses       Date:  2008-03       Impact factor: 2.205

8.  Characterization of T-cell responses in macaques immunized with a single dose of HIV DNA vaccine.

Authors:  Géraldine Arrode-Brusés; Darlene Sheffer; Ramakrishna Hegde; Sukbir Dhillon; Zhengian Liu; François Villinger; Opendra Narayan; Yahia Chebloune
Journal:  J Virol       Date:  2009-11-18       Impact factor: 5.103

9.  Detection of diverse hepatitis C virus (HCV)-specific cytotoxic T lymphocytes in peripheral blood of infected persons by screening for responses to all translated proteins of HCV.

Authors:  D K Wong; D D Dudley; P B Dohrenwend; G M Lauer; R T Chung; D L Thomas; B D Walker
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

10.  Decreased frequency of cytomegalovirus (CMV)-specific CD4+ T lymphocytes in simian immunodeficiency virus-infected rhesus macaques: inverse relationship with CMV viremia.

Authors:  Amitinder Kaur; Corrina L Hale; Bradley Noren; Nadine Kassis; Meredith A Simon; R Paul Johnson
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.